Multiple myeloma (MM) is the second most common blood cancer. Treatments for MM
include corticosteroids, alkylating agents, anthracyclines, proteasome inhibitors …

Based on the clinical features of myeloma and related malignancies of plasma cells, it has
been possible to generate a model system of myeloma progression from a normal plasma …

Some genetic abnormalities of multiple myeloma (MM) detected more than two decades ago
remain major prognostic factors. In recent years, the introduction of cutting-edge genomic …

To obtain a comprehensive genomic profile of presenting multiple myeloma cases we
performed high-resolution single nucleotide polymorphism mapping array analysis in 114 …

Nuclear receptor-binding SET domain-containing 2 (NSD2) is the primary enzyme
responsible for the dimethylation of lysine 36 of histone 3 (H3K36), a mark associated with …

In the era of new and mostly effective therapeutic protocols, multiple myeloma still tends to
be a hard-to-treat hematologic cancer. This hallmark of the disease is in fact a sequel to drug …

Cancer is perceived as a heterogeneous group of diseases that is characterized by aberrant
patterns of gene expression. In the last decade, an increasing amount of data has pointed to …

The nuclear receptor–binding SET Domain (NSD) family of histone H3 lysine 36
methyltransferases is comprised of NSD1, NSD2 (MMSET/WHSC1), and NSD3 (WHSC1L1) …

The methylation of histone H3 at lysine 36 (H3K36me) is essential for maintaining genomic
stability. Indeed, this methylation mark is essential for proper transcription, recombination …

To date, little evidence of miRNA expression/deregulation in multiple myeloma has been
reported. To characterize miRNA in the context of the major multiple myeloma molecular …